p53  ||| S:0 E:4 ||| NN
gene  ||| S:4 E:9 ||| NN
therapy  ||| S:9 E:17 ||| NN
using  ||| S:17 E:23 ||| VBG
RNA  ||| S:23 E:27 ||| NNP
interference  ||| S:27 E:40 ||| NN
p53  ||| S:40 E:44 ||| NN
gene ||| S:44 E:48 ||| NN
,  ||| S:48 E:50 ||| ,
discovered  ||| S:50 E:61 ||| VBD
almost  ||| S:61 E:68 ||| RB
35  ||| S:68 E:71 ||| CD
years  ||| S:71 E:77 ||| NNS
ago ||| S:77 E:80 ||| RB
,  ||| S:80 E:82 ||| ,
keeps  ||| S:82 E:88 ||| VBZ
the  ||| S:88 E:92 ||| DT
main  ||| S:92 E:97 ||| JJ
role  ||| S:97 E:102 ||| NN
in  ||| S:102 E:105 ||| IN
cell  ||| S:105 E:110 ||| NN
cycle  ||| S:110 E:116 ||| NN
control ||| S:116 E:123 ||| NN
,  ||| S:123 E:125 ||| ,
apoptosis  ||| S:125 E:135 ||| JJ
pathways  ||| S:135 E:144 ||| NN
and  ||| S:144 E:148 ||| CC
transcription.  ||| S:148 E:163 ||| CD
p53  ||| S:163 E:167 ||| NN
gene  ||| S:167 E:172 ||| NN
is  ||| S:172 E:175 ||| VBZ
found  ||| S:175 E:181 ||| VBN
mutated  ||| S:181 E:189 ||| VBN
in  ||| S:189 E:192 ||| IN
more  ||| S:192 E:197 ||| JJR
than  ||| S:197 E:202 ||| IN
50 ||| S:202 E:204 ||| CD
%  ||| S:204 E:206 ||| NN
of  ||| S:206 E:209 ||| IN
all  ||| S:209 E:213 ||| DT
human  ||| S:213 E:219 ||| JJ
cancers  ||| S:219 E:227 ||| NNS
in  ||| S:227 E:230 ||| IN
different  ||| S:230 E:240 ||| JJ
locations ||| S:240 E:249 ||| NNS
.  ||| S:249 E:251 ||| .
Many  ||| S:251 E:256 ||| JJ
structures  ||| S:256 E:267 ||| NNS
from  ||| S:267 E:272 ||| IN
viral  ||| S:272 E:278 ||| JJ
to  ||| S:278 E:281 ||| TO
non  ||| S:281 E:285 ||| VB
viral  ||| S:285 E:291 ||| NNS
were  ||| S:291 E:296 ||| VBD
designed  ||| S:296 E:305 ||| VBN
to  ||| S:305 E:308 ||| TO
incorporate  ||| S:308 E:320 ||| VB
and  ||| S:320 E:324 ||| CC
deliver  ||| S:324 E:332 ||| VB
in  ||| S:332 E:335 ||| IN
appropriate  ||| S:335 E:347 ||| JJ
conditions  ||| S:347 E:358 ||| NNS
forms  ||| S:358 E:364 ||| NNS
of  ||| S:364 E:367 ||| IN
p53  ||| S:367 E:371 ||| NN
gene  ||| S:371 E:376 ||| NN
or  ||| S:376 E:379 ||| CC
its  ||| S:379 E:383 ||| PRP$
transcripts ||| S:383 E:394 ||| NNS
,  ||| S:394 E:396 ||| ,
systemically  ||| S:396 E:409 ||| VBG
to  ||| S:409 E:412 ||| TO
target  ||| S:412 E:419 ||| VB
tumor  ||| S:419 E:425 ||| NN
cells  ||| S:425 E:431 ||| NNS
and  ||| S:431 E:435 ||| CC
to  ||| S:435 E:438 ||| TO
eliminate  ||| S:438 E:448 ||| VB
them  ||| S:448 E:453 ||| PRP
through  ||| S:453 E:461 ||| IN
apoptosis  ||| S:461 E:471 ||| NN
or  ||| S:471 E:474 ||| CC
to  ||| S:474 E:477 ||| TO
restore  ||| S:477 E:485 ||| VB
the  ||| S:485 E:489 ||| DT
normal  ||| S:489 E:496 ||| JJ
tumor  ||| S:496 E:502 ||| NN
suppressor  ||| S:502 E:513 ||| NN
gene  ||| S:513 E:518 ||| NN
role ||| S:518 E:522 ||| NN
.  ||| S:522 E:524 ||| .
Each  ||| S:524 E:529 ||| DT
delivery  ||| S:529 E:538 ||| NN
system  ||| S:538 E:545 ||| NN
presents  ||| S:545 E:554 ||| VBZ
advantages  ||| S:554 E:565 ||| NNS
and  ||| S:565 E:569 ||| CC
low  ||| S:569 E:573 ||| JJ
performance  ||| S:573 E:585 ||| NN
in  ||| S:585 E:588 ||| IN
relation  ||| S:588 E:597 ||| NN
to  ||| S:597 E:600 ||| TO
immune  ||| S:600 E:607 ||| JJ
system  ||| S:607 E:614 ||| NN
recognition  ||| S:614 E:626 ||| NN
and  ||| S:626 E:630 ||| CC
acceptance ||| S:630 E:640 ||| NN
.  ||| S:640 E:642 ||| .
One  ||| S:642 E:646 ||| CD
of  ||| S:646 E:649 ||| IN
the  ||| S:649 E:653 ||| DT
major  ||| S:653 E:659 ||| JJ
discoveries  ||| S:659 E:671 ||| NNS
in  ||| S:671 E:674 ||| IN
the  ||| S:674 E:678 ||| DT
last  ||| S:678 E:683 ||| JJ
years ||| S:683 E:688 ||| NNS
,  ||| S:688 E:690 ||| ,
silencing  ||| S:690 E:700 ||| VBG
of  ||| S:700 E:703 ||| IN
RNA ||| S:703 E:706 ||| NNP
,  ||| S:706 E:708 ||| ,
represents  ||| S:708 E:719 ||| VBZ
a  ||| S:719 E:721 ||| DT
powerful  ||| S:721 E:730 ||| JJ
tool  ||| S:730 E:735 ||| NN
for  ||| S:735 E:739 ||| IN
inhibiting  ||| S:739 E:750 ||| JJ
post  ||| S:750 E:755 ||| NN
transcriptional  ||| S:755 E:771 ||| NN
control  ||| S:771 E:779 ||| NN
of  ||| S:779 E:782 ||| IN
gene  ||| S:782 E:787 ||| NN
expression ||| S:787 E:797 ||| NN
.  ||| S:797 E:799 ||| .
According  ||| S:799 E:809 ||| VBG
to  ||| S:809 E:812 ||| TO
several  ||| S:812 E:820 ||| JJ
studies ||| S:820 E:827 ||| NNS
,  ||| S:827 E:829 ||| ,
the  ||| S:829 E:833 ||| DT
RNA  ||| S:833 E:837 ||| NNP
silencing  ||| S:837 E:847 ||| JJ
technology  ||| S:847 E:858 ||| NN
for  ||| S:858 E:862 ||| IN
p53  ||| S:862 E:866 ||| NN
transcripts  ||| S:866 E:878 ||| NNS
together  ||| S:878 E:887 ||| RB
with  ||| S:887 E:892 ||| IN
other  ||| S:892 E:898 ||| JJ
carriers  ||| S:898 E:907 ||| NNS
or  ||| S:907 E:910 ||| CC
transporters  ||| S:910 E:923 ||| NN
at  ||| S:923 E:926 ||| IN
nano  ||| S:926 E:931 ||| JJ
level  ||| S:931 E:937 ||| NN
can  ||| S:937 E:941 ||| MD
be  ||| S:941 E:944 ||| VB
used  ||| S:944 E:949 ||| VBN
for  ||| S:949 E:953 ||| IN
creating  ||| S:953 E:962 ||| VBG
new  ||| S:962 E:966 ||| JJ
therapeutic  ||| S:966 E:978 ||| JJ
models ||| S:978 E:984 ||| NNS
.  ||| S:984 E:986 ||| .
RNA  ||| S:986 E:990 ||| NNP
interference  ||| S:990 E:1003 ||| NN
for  ||| S:1003 E:1007 ||| IN
p53  ||| S:1007 E:1011 ||| NN
uses  ||| S:1011 E:1016 ||| VBZ
different  ||| S:1016 E:1026 ||| JJ
double-stranded  ||| S:1026 E:1042 ||| NN
( ||| S:1042 E:1043 ||| -LRB-
ds ||| S:1043 E:1045 ||| LS
)  ||| S:1045 E:1047 ||| -RRB-
molecules  ||| S:1047 E:1057 ||| NNS
like  ||| S:1057 E:1062 ||| IN
short  ||| S:1062 E:1068 ||| JJ
interfering  ||| S:1068 E:1080 ||| NNS
( ||| S:1080 E:1081 ||| -LRB-
si ||| S:1081 E:1083 ||| LS
)  ||| S:1083 E:1085 ||| -RRB-
RNA  ||| S:1085 E:1089 ||| NNP
and ||| S:1089 E:1092 ||| CC
,  ||| S:1092 E:1094 ||| ,
despite  ||| S:1094 E:1102 ||| IN
the  ||| S:1102 E:1106 ||| DT
difficulty  ||| S:1106 E:1117 ||| NN
of  ||| S:1117 E:1120 ||| IN
introducing  ||| S:1120 E:1132 ||| VBG
them  ||| S:1132 E:1137 ||| PRP
into  ||| S:1137 E:1142 ||| IN
mammalian  ||| S:1142 E:1152 ||| JJ
cells  ||| S:1152 E:1158 ||| NNS
due  ||| S:1158 E:1162 ||| JJ
to  ||| S:1162 E:1165 ||| TO
immune  ||| S:1165 E:1172 ||| JJ
system  ||| S:1172 E:1179 ||| NN
response ||| S:1179 E:1187 ||| NN
,  ||| S:1187 E:1189 ||| ,
it  ||| S:1189 E:1192 ||| PRP
can  ||| S:1192 E:1196 ||| MD
be  ||| S:1196 E:1199 ||| VB
exploited  ||| S:1199 E:1209 ||| VBN
in  ||| S:1209 E:1212 ||| IN
cancer  ||| S:1212 E:1219 ||| NN
therapy ||| S:1219 E:1226 ||| NN
.  ||| S:1226 E:1228 ||| .
